|
**Overview**: GM2 Gangliosidosis Panel**Introduction**: The GM2 Gangliosidosis Panel is a diagnostic tool designed to screen for Tay-Sachs/Sandhoff disease using whole blood samples. In India, Tay-Sachs (HEXA deficiency) and Sandhoff (HEXB deficiency) are rare but devastating lysosomal storage disorders (~1 in 100,000â€"300,000), presenting in infantile form with developmental regression, cherry-red spot, seizures, and death by age 4, or juvenile/adult forms with ataxia/motor decline. High morbidity from underdiagnosis in rural/low-SES children with unexplained regression, limited genetic/enzyme labs, delayed supportive care leading to rapid neurodegeneration. Per molecular pathology practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for HEXA/HEXB mutations and hexosaminidase A/B activity over 1-2 days with high accuracy, valuable for confirming diagnosis and carrier screening in high-risk communities. This diagnostic falls under genetic disorder screening and targets infants/children with neuroregression or family history, addressing accurate detection to guide palliative care and counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing lysosomal storage burden. Its whole blood-based approach ensures reliable enzyme/mutation analysis.**Other Names**: GM2 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: HEXA/HEXB testing standard; in India, used in rare disease clinics.**Purpose**: The test assesses 4 parameters including HEXA gene mutation to guide Tay-Sachs/Sandhoff screening, confirm deficiency, inform counseling.**Test Parameters**: 1. HEXA Gene Mutation, 2. HEXB Gene Mutation, 3. Hexosaminidase A Activity, 4. Hexosaminidase B Activity.**Pretest Condition**: No fasting required; patients should report developmental regression or family history.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for analysis).**Medical History**: Patients should provide details on regression onset, seizures, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed GM2 including neurodegeneration, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR and enzyme assay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low enzyme activity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Mutation/low activity confirms Tay-Sachs/Sandhoff, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Pediatric neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: Urine oligosaccharides, MRI brain for confirmation.**Test Limitations**: May miss rare variants; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023. |
